Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
Editorials & Other Articles
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Latest Breaking News
In reply to the discussion: Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? [View all]
LetMyPeopleVote
(183,882 posts)41. MS NOW- White House denies Trump applied for 'compassionate use' for weight loss drug
An unnamed 79-year-old man was reportedly granted special access to the drug retatrutide through a “compassionate use” program.
White House denies Trump applied for ‘compassionate use’ for weight loss drug.
— TheBlackPage (Woke, DEI forever against fascism) (@theblackpage.bsky.social) 2026-06-23T23:21:33.054Z
An unnamed 79-year-old man was reportedly granted special access to the drug retatrutide through a “compassionate use†program.
www.ms.now/news/white-h...
https://www.ms.now/news/white-house-trump-weight-loss-drug
The White House on Tuesday denied that President Donald Trump applied for access to an experimental obesity drug not yet on the market after Stat News reported that a 79-year-old man was approved to take it.
The health and science news outlet Stat News reported that the Food and Drug Administration and drug manufacturer Eli Lilly allowed one person — a 79-year-old man — special access to the drug retatrutide through a “compassionate use” program, citing three sources familiar with the matter. Those sources, Stat News reported, requested anonymity due to fear of reprisals.
According to the FDA, compassionate use is a “pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.”....
But on Tuesday, hours after the Stat News report was published, White House spokesman Kush Desai said on X that the “application was not for the President.” He went on to publicly bash the report’s author, Lizzy Lawrence, accusing her of being an “unserious gossip columnist.”
Lawrence responded on X that she had asked Desai, the FDA and HHS “multiple times” on Monday whether the application was for Trump. “No one answered my question directly,” she wrote. Desai called the report “baseless speculation” in a follow-up post.
The health and science news outlet Stat News reported that the Food and Drug Administration and drug manufacturer Eli Lilly allowed one person — a 79-year-old man — special access to the drug retatrutide through a “compassionate use” program, citing three sources familiar with the matter. Those sources, Stat News reported, requested anonymity due to fear of reprisals.
According to the FDA, compassionate use is a “pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.”....
But on Tuesday, hours after the Stat News report was published, White House spokesman Kush Desai said on X that the “application was not for the President.” He went on to publicly bash the report’s author, Lizzy Lawrence, accusing her of being an “unserious gossip columnist.”
Lawrence responded on X that she had asked Desai, the FDA and HHS “multiple times” on Monday whether the application was for Trump. “No one answered my question directly,” she wrote. Desai called the report “baseless speculation” in a follow-up post.
The patient who received this drug "suffered from refractory obesity with obstructive sleep apnea and pulmonary hypertension."
National Institutes of Health Senior Clinician Ranganath Muniyappa requested the drug to treat the patient, who suffered from refractory obesity with obstructive sleep apnea and pulmonary hypertension, Stat News reported. Muniyappa, who did not respond to the outlet’s request for comment, reportedly recommended against bariatric surgery because of the patient’s age and medical conditions.
The patient also took tirzepatide, an FDA-approved obesity drug by Lilly, for one year, “but experienced only moderate weight loss,” Stat News reported, citing sources familiar with the matter.
The patient also took tirzepatide, an FDA-approved obesity drug by Lilly, for one year, “but experienced only moderate weight loss,” Stat News reported, citing sources familiar with the matter.
trump has not lost any significant weight over the last year and so that does NOT rule trump out. I have obstructive sleep apnea and have been using a CPAP for a very long time. I seriously doubt that trump is capable of using a CPAP machine correctly and consistently which could account for trump's strange hours and trump falling asleep in meetings.
Edit history
Please sign in to view edit histories.
Recommendations
0 members have recommended this reply (displayed in chronological order):
41 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
RecommendedHighlight replies with 5 or more recommendations
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
RecommendedHighlight replies with 5 or more recommendations
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? [View all]
mahatmakanejeeves
Tuesday
OP
According to the RawStory link, the patient has obstructive sleep apnea and pulmonary hypertension,
LetMyPeopleVote
Tuesday
#7
MS NOW- White House denies Trump applied for 'compassionate use' for weight loss drug
LetMyPeopleVote
Tuesday
#41